{"_":"EXPRESS: Serial measurement of serum pancreatic lipase immunoreactivity and trypsin-like immunoreactivity concentrations in cats with chronic enteropathy.","b":[""]}

Serial fPLI and fTLI monitoring may reveal concurrent pancreatitis or EPI in cats with IRE or LGITL.

This observational study investigated serial serum feline pancreatic lipase immunoreactivity (fPLI) and trypsin-like immunoreactivity (fTLI) concentrations in 60 cats diagnosed with chronic enteropathy (CE), categorized as immunosuppressive-responsive enteropathy (IRE, n=22), food-responsive enteropathy (FRE, n=7), or low-grade intestinal T-cell lymphoma (LGITL, n=32). A total of 252 fPLI and 245 fTLI serum samples were evaluated at initial presentation and during follow-up reexaminations. At initial presentation, fPLI concentrations indicative of pancreatitis were identified in 3/60 cats (1 IRE, 2 LGITL), with an additional 8 cats (4 IRE, 4 LGITL) demonstrating elevated fPLI during treatment, totaling 24/252 samples. fTLI concentrations consistent with exocrine pancreatic insufficiency (EPI) were detected in 2/60 cats (both IRE) at presentation and during reexamination (3/245 samples). Notably, no cats with FRE exhibited abnormal fPLI or fTLI values at any time point. These findings suggest that concurrent or developing pancreatitis may occur in a subset of cats with IRE or LGITL during treatment, and EPI may occasionally develop in cats with IRE. The fluctuation of pancreatic biomarkers over time underscores the potential value of serial monitoring in CE cases. The authors acknowledge that the long-term clinical significance of these pancreatic enzyme fluctuations remains unclear and warrants further investigation. Clinicians should be aware of possible pancreatic comorbidities in cats with CE, particularly those with IRE or LGITL.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.